The Valley Desk

ArticleBiological psychiatry global open sciencePublished

Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a Study

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Biological psychiatry global open science
Published
Subject terms
Genetic markers; Bipolar disorder; Neuroimmunology; Randomized Clinical Trial; Patient-reported Outcomes; Montgomery–åsberg Depression Rating Scale
PubMed ID
42181295
PubMed Central ID
PMC13196505
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal